Other secondary sequelae of treatments for Myeloproliferative disorders

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 10, 2002, Pages 22-27

  Gilbert, Harriet S ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; HYDROXYUREA;

ACUTE LEUKEMIA; ANOREXIA; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FLU LIKE SYNDROME; HEADACHE; HEART PALPITATION; HUMAN; LEUKEMOGENESIS; MENTAL DISEASE; MUTAGENESIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; THROMBOCYTHEMIA; THROMBOSIS; VERTIGO;

EID: 0036300986     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70149-8     Document Type: Review

References (33)

1. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
2. Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythemia vera and essential thrombocythemia
3. Anagrelide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythemia
4. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia
5. Essential thrombocythemia transformed to acute myelogenous leukemia with t(3;17)(p24;q12), del(5)(q13q34) after treatment with carboquone and hydroxyurea
6. Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group
7. Thrombotic complications in essential thrombocythemia with relatively low platelet counts
8. 9/L be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
9. 9/L. Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC)
10. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia
11. Long term treatment of myeloproliferative disease with interferon-alpha-2b: Feasibility and efficacy
12. Hemopoietic stem cell transplantation for advanced polycythemia vera or essential thrombocythemia
13. Interferon alpha in the treatment of polycythemia vera
14. From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera
15. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
16. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial
17. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders
18. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
19. Plasma erythropoietin in essential thrombocythaemia: At diagnosis and in response to myelosuppressive treatment
20. Neurologic manifestations of essential thrombocythemia
21. Neurologic and visual symptoms in essential thrombocythemia: Efficacy of low-dose aspirin
22. Erythromelalgia: A pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera
23. Erythromelalgia and vascular complications in polycythemia vera
24. Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera
25. The cutaneous side-effects of hydroxyurea
26. Hydroxyurea-induced skin ulceration in myeloproliferative disorders
27. Oral ulcers caused by hydroxyurea
28. Leg ulcer in hydroxyurea-treated patients
29. Hydroxyurea-induced leg ulcers
30. Hydroxyurea as a cause of drug fever
31. Hydroxyurea-induced hypersensitive pneumonitis
32. Anagrelide-induced cardiomyopathy
33. Long-term use of anagrelide in young patients with essential thrombocythemia